Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023
July 27, 2023 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, July 27, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its second quarter earnings conference call on...
Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment
July 24, 2023 08:00 ET
|
Myriad Genetics, Inc.
RiskScore is the first validated risk model that includes breast density, personal/family history and genetic markers This comprehensive model is expected to identify more patients that could benefit...
Myriad Genetics Announces New $90 Million Asset-Based Credit Facility
July 06, 2023 08:30 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, July 06, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has established a new $90 million...
Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform
June 12, 2023 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, June 12, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced an agreement with The University of Texas...
Myriad Genetics to Participate in Goldman Sachs Healthcare Conference
June 07, 2023 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, June 07, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, president and CEO, will...
Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023
June 01, 2023 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, June 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be highlighting new studies and the recent expansion...
Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics
May 31, 2023 08:00 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, May 31, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has named Adam Brufsky, MD, PhD, FACP,...
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
May 24, 2023 16:05 ET
|
Myriad Genetics, Inc.
Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE® SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a...
Myriad Genetics Earns 2023 Great Place to Work Certification™
May 08, 2023 16:05 ET
|
Myriad Genetics, Inc.
SALT LAKE CITY, May 08, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has achieved the Great Place to Work®...
Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range
May 03, 2023 16:05 ET
|
Myriad Genetics, Inc.
Highlights: First quarter testing volumes grew 21% year-over-year and 10% sequentially, excluding contributions from the SneakPeek® Early Gender DNA Test.In the first quarter: Hereditary cancer...